BIVI
BIOVIE INC.
NASDAQ · Healthcare · Biotechnology · US
$1.37
+14.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.29
From 52W high−39.91%
Volume180545.00
Market cap$11.90M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.29
From 52W high
−39.91%
Volume
180545.00
Market cap
$11.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
42.3
MomentumView details →
1D Return
+14.17%
YTD Return
+13.79%
SummaryUpdated Jun 1, 2026
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biotechnology company founded in 2013 and based in Carson City, Nevada. Originally incorporated as NanoAntibiotics, Inc., the company rebranded to BioVie Inc. in July 2016 and went public in September 2020. BioVie focuses on discovering, developing, and commercializing novel drug therapies, with a particular emphasis on treatments for neurological disorders and liver diseases. The company operates as a pure-play research and development organization with no current revenue-generating products, as all of its therapeutic candidates remain in various stages of clinical trials.
Similar companies
Latest newsMore news →
BioVie said its abstracts on Phase 2 trial results for bezisterim in Long COVID and Parkinson’s disease were accepted as poster presentations at the American Neurological Association’s annual meeting, scheduled for October 17–20 in San Diego.5d agoBioVie announced topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for treating neurological symptoms associated with Long COVID, reporting statistically significant benefits in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise.34d agoBioVie Inc requested an End-of-Phase 2 meeting with the US Food and Drug Administration to advance its Phase 3 development program for bezisterim in Parkinson's disease.41d ago